7 November 2017 - Auryxia is the only oral treatment option available today developed and approved specifically for adults living with iron deficiency anaemia and chronic kidney disease, not on dialysis.

Keryx Biopharmaceuticals today announced that the U.S. FDA has approved Auryxia for an additional indication. The approval is for the treatment of iron deficiency anaemia in adults with chronic kidney disease, not on dialysis. 

Auryxia was originally approved in September 2014 for the control of serum phosphorus levels in people with chronic kidney disease who require dialysis.

Read Keryx Biopharmaceuticals press release